Eurazeo, a global investment company through its Mid-Large Buyout strategy, has acquired a majority stake in Cranial Technologies, a provider in infant plagiocephaly treatment. The investment is worth over $200 million along with equity rollover from the existing management team. Sidley Austin represented Eurazeo on the deal.

Cranial Technologies is a treatment provider and manufacturer of helmets used for infants with forms of plagiocephaly, brachycephaly and scaphocephaly. The firm has delivered care to over 300,000 babies using its FDA-approved DOC Band cranial orthotic. Cranial Technologies delivers its helmets across 80 operated locations in the United States and six licensed clinics internationally.

“We are delighted to announce the acquisition of Cranial Technologies, the fifth investment for Eurazeo’s Mid-Large buyout strategy in the US,” added Marc Frappier, member of the executive board, managing partner of Mid-Large Buyout. “We are proud to be the partner of choice for mid-sized companies with strong development ambitions. With Eurazeo, Cranial Technologies will benefit from a deep healthcare expertise, a team of committed experts, a global network and financial resources.”

“Since Cranial Technologies was founded over 30 years ago, our mission has been to provide the best possible treatment, experience and outcome for every family who seeks our care,” commented Debbie James, CEO of Cranial Technologies. “We are excited to work with Eurazeo, a partner not only with an impressive track record in scaling companies, but one who believes in our mission alongside our team. Together, we look forward to welcoming new families around the world to our clinics.“